Previous 10 | Next 10 |
The following slide deck was published by Radius Health, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Radius Health, Inc. 2022 Q4 - Results - Earnings Call Presentation
Radius Health press release (NASDAQ:RDUS): Q4 Non-GAAP EPS of $0.05 misses by $0.03. Revenue of $65.1M (+3.7% Y/Y) beats by $2.04M. For further details see: Radius Health Non-GAAP EPS of $0.05 misses by $0.03, revenue of $65.1M beats by $2.04M
Q4 2021 TYMLOS ® net revenue of $65 million vs. $60 million in Q4 2020, up 9% This is a record quarter – over 18 quarters – since the launch in May 2017 FY 2021 TYMLOS Net Revenue of $219 vs. $208 million in FY 2020, up 5% Net Loss reduced by ~36%: ($7...
Radius Health (NASDAQ:RDUS) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open. The consensus EPS Estimate is $0.08 (+134.8% Y/Y) and the consensus Revenue Estimate is $63.06M (+0.4% Y/Y). Over the last 2 years, RDUS has beaten EPS estimates 25% of the...
BOSTON, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (NASDAQ: RDUS) announced today that it will release its fourth quarter and full year 2021 financial results on Thursday, February 24, 2022. The Company will host a conference call and live audio webcast at 8:30 a.m. ET to discuss...
Completion of three pivotal trials in 2021 enables restructuring of the operating infrastructure Non-Sales headcount reduced by approximately 20% Reductions focused on areas that supported abaloparatide clinical and regulatory activities Company to provide Q4 & FY 2021 r...
Radius Health (NASDAQ:RDUS) announced that the FDA approved the removal of the boxed warning linked to TYMLOS on the risk of osteosarcoma. TYMLOS is an FDA-approved medication marketed by the company for postmenopausal women with osteoporosis. The labeling update on TYMLOS follows a regulator...
FDA approved the removal of the boxed warning from the TYMLOS label, effective December 22, 2021 The boxed warning had referred to the potential risk of osteosarcoma Action follows review of long-term post-marketing data for TYMLOS and PTH class of drugs BOSTON, Dec. 23, 2...
EMERYVILLE, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced the appointment of Jessica Hopfield, Ph.D. to the Berkeley Lights’ Board of Directors as an independent director, effective December 15, 2021. ...
Radius Health (RDUS +3.3%) as 10% owner, Rubric Capital Management LP bought ~462.24K shares at $6.77 - $7.08 for a total transaction value of ~$3.2M. A quick look at the company's ownership structure: For further details see: Radius Health up ~4% as owner buys ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...
A look at the top 10 most actives in the United States Ocean Power Technologies Inc. (OPTT) rose 54.4% to $0.4264 on volume of 158,036,142 shares Versus Systems Inc. (VS) rose 73.5% to $2.29 on volume of 40,036,424 shares Tesla Inc. (TSLA) rose 5.3% to $220.97 on volume of 32,375,487 shar...
Ferrous, Nonferrous and Finished Steel Sales Volumes Up Sequentially Radius Board Declares Quarterly Dividend PORTLAND, Ore., July 02, 2024 (GLOBE NEWSWIRE) -- Radius Recycling, Inc. (NASDAQ: RDUS) today reported results for the third quarter of fiscal 2024 ended May 31, 2024. ...